950 related articles for article (PubMed ID: 20435236)
1. Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.
Scheiman JM; Hindley CE
Clin Ther; 2010 Apr; 32(4):667-77. PubMed ID: 20435236
[TBL] [Abstract][Full Text] [Related]
2. Canadian consensus guidelines on long-term nonsteroidal anti-inflammatory drug therapy and the need for gastroprotection: benefits versus risks.
Rostom A; Moayyedi P; Hunt R;
Aliment Pharmacol Ther; 2009 Mar; 29(5):481-96. PubMed ID: 19053986
[TBL] [Abstract][Full Text] [Related]
3. The relative efficacies of gastroprotective strategies in chronic users of nonsteroidal anti-inflammatory drugs.
Targownik LE; Metge CJ; Leung S; Chateau DG
Gastroenterology; 2008 Apr; 134(4):937-44. PubMed ID: 18294634
[TBL] [Abstract][Full Text] [Related]
4. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.
Turajane T; Wongbunnak R; Patcharatrakul T; Ratansumawong K; Poigampetch Y; Songpatanasilp T
J Med Assoc Thai; 2009 Dec; 92 Suppl 6():S19-26. PubMed ID: 20128070
[TBL] [Abstract][Full Text] [Related]
5. Management of patients on nonsteroidal anti-inflammatory drugs: a clinical practice recommendation from the First International Working Party on Gastrointestinal and Cardiovascular Effects of Nonsteroidal Anti-inflammatory Drugs and Anti-platelet Agents.
Chan FK; Abraham NS; Scheiman JM; Laine L;
Am J Gastroenterol; 2008 Nov; 103(11):2908-18. PubMed ID: 18853980
[TBL] [Abstract][Full Text] [Related]
6. Coxibs versus combination NSAID and PPI therapy for chronic pain: an exploration of the risks, benefits, and costs.
Hur C; Chan AT; Tramontano AC; Gazelle GS
Ann Pharmacother; 2006 Jun; 40(6):1052-63. PubMed ID: 16720709
[TBL] [Abstract][Full Text] [Related]
7. NSAIDs-induced gastrointestinal damage. Review.
Arroyo M; Lanas A
Minerva Gastroenterol Dietol; 2006 Sep; 52(3):249-59. PubMed ID: 16971869
[TBL] [Abstract][Full Text] [Related]
8. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis.
Wang X; Tian HJ; Yang HK; Wanyan P; Peng YJ
Eur J Gastroenterol Hepatol; 2011 Oct; 23(10):876-80. PubMed ID: 21900785
[TBL] [Abstract][Full Text] [Related]
9. A regional audit of the use of COX-2 selective non-steroidal anti-inflammatory drugs (NSAIDs) in rheumatology clinics in the West Midlands, in relation to NICE guidelines.
Price-Forbes AN; Callaghan R; Allen ME; Rowe IF
Rheumatology (Oxford); 2005 Jul; 44(7):921-4. PubMed ID: 15827035
[TBL] [Abstract][Full Text] [Related]
10. NSAID-induced gastrointestinal damage: current clinical management and recommendations for prevention.
Lanas A; Ferrandez A
Chin J Dig Dis; 2006; 7(3):127-33. PubMed ID: 16808792
[TBL] [Abstract][Full Text] [Related]
11. Gastroprotective therapy and risk of gastrointestinal ulcers: risk reduction by COX-2 therapy.
Wolfe F; Anderson J; Burke TA; Arguelles LM; Pettitt D
J Rheumatol; 2002 Mar; 29(3):467-73. PubMed ID: 11908558
[TBL] [Abstract][Full Text] [Related]
12. Prevention of anti-inflammatory drug-induced gastrointestinal damage: benefits and risks of therapeutic strategies.
Lanas A; Hunt R
Ann Med; 2006; 38(6):415-28. PubMed ID: 17008305
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular and gastrointestinal toxicity of selective cyclo-oxygenase-2 inhibitors in man.
Dajani EZ; Islam K
J Physiol Pharmacol; 2008 Aug; 59 Suppl 2():117-33. PubMed ID: 18812633
[TBL] [Abstract][Full Text] [Related]
14. Primer: managing NSAID-induced ulcer complications--balancing gastrointestinal and cardiovascular risks.
Chan FK
Nat Clin Pract Gastroenterol Hepatol; 2006 Oct; 3(10):563-73. PubMed ID: 17008926
[TBL] [Abstract][Full Text] [Related]
15. Nonsteroidal anti-inflammatory drugs (NSAIDs), cyxlooxygenase-2 selective inhibitors (coxibs) and gastrointestinal harm: review of clinical trials and clinical practice.
Moore RA; Derry S; Phillips CJ; McQuay HJ
BMC Musculoskelet Disord; 2006 Oct; 7():79. PubMed ID: 17054784
[TBL] [Abstract][Full Text] [Related]
16. Proton pump inhibitor co-therapy with nonsteroidal anti-inflammatory drugs--nice or necessary?
Laine L
Rev Gastroenterol Disord; 2004; 4 Suppl 4():S33-41. PubMed ID: 15580145
[TBL] [Abstract][Full Text] [Related]
17. Underutilization of preventive strategies in patients receiving NSAIDs.
Sturkenboom MC; Burke TA; Dieleman JP; Tangelder MJ; Lee F; Goldstein JL
Rheumatology (Oxford); 2003 Nov; 42 Suppl 3():iii23-31. PubMed ID: 14585915
[TBL] [Abstract][Full Text] [Related]
18. Impact of compliance with proton pump inhibitors on NSAID treatment.
Duh MS; Gosselin A; Luo R; Lohoues H; Lewis BE; Crawley JA
Am J Manag Care; 2009 Oct; 15(10):681-8. PubMed ID: 19845420
[TBL] [Abstract][Full Text] [Related]
19. COX-2 inhibitors: complex association with lower risk of hospitalization for gastrointestinal events compared to traditional NSAIDs plus proton pump inhibitors.
van der Linden MW; Gaugris S; Kuipers EJ; van Herk-Sukel MP; van den Bemt BJ; Sen SS; Herings RM
Pharmacoepidemiol Drug Saf; 2009 Oct; 18(10):880-90. PubMed ID: 19593747
[TBL] [Abstract][Full Text] [Related]
20. Strategies to reduce the GI risks of antiplatelet therapy.
Scheiman JM
Rev Cardiovasc Med; 2005; 6 Suppl 4():S23-31. PubMed ID: 17710073
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]